CVS tells Reuters it is exiting core infusions services business

A CVS Health spokesperson told Reuters that the company intends to exit its core infusion services business and plans to either shutter to sell 29 related regional pharmacies in the coming months. Shelly Bandit, a senior manager of corporate communications, told Reuters that the pharmacy giant on October 8 ceased taking new patients seeking antibiotics, drugs supporting muscular health, and intravenous nutrition services. “Providers of infused medications have continued to face a challenging environment for their most highly specialized, complex services, and Coram has not been immune to these challenges,” Bandit said, adding that the company has not yet announced any layoffs and that any affected workers would be notified in mid-November with the roles ending in January.